🐦 推特OkloCodex · 实盘不做把握 6/10不做原因:无增量信息
北京时间·🕒 发布 09-04 22:29:41时区推断·⟳ 抓取 09-04 22:30:13·⚡ 决策 09-05 02:03:40 +3h33m·52.7 天前
Oklo重提Groves反应堆临界与2027年初同位素收入目标，但缺少新增可交易事实
本次社媒内容方向偏正面，但核心事实已由Oklo在2026-08-06和2026-03-17公开披露；没有新增订单金额、监管批准、收入确认或部署时间表上修，难以形成盘中追入Oklo Inc.（OKLO.US）的新增edge。
📄 原文Oklo@oklo↗ 原文
Reaching criticality at Groves was a major milestone. It was also just the beginning. In less than a year, Oklo built o…
不做 Oklo Inc.（OKLO.US）
不做Oklo Inc.（OKLO.US）：本次X帖子主要复述已公告的Groves临界和同位素收入目标，缺少新增金额、客户、许可或时间表上修，短线edge不足。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Oklo本次帖子把Groves临界包装为商业化执行能力证明，并重申2027年初同位素收入目标；但Groves临界和NRC许可均已有公司官网公告支撑，当前帖子更像传播/投资者叙事强化而非新催化。对Oklo Inc.（OKLO.US）长期基本面是正向信号，但短线交易缺少新的可量化收入增量和未消化信息。
消息传播链
- Oklo已正式公告Groves Isotope Test Reactor达到首次临界，是本次帖子所述核心事实的早期一手披露。
- Oklo此前已公告Atomic Alchemy获得NRC材料许可，支持其Idaho Radiochemistry Laboratory开展同位素处理和销售准备。
- Oklo在X上重述Groves临界经验，并称将推进商业规模、同位素收入、动力和燃料项目。
关键理由
- Groves临界证明Oklo具备更快推进测试反应堆建设、启动和运行的执行记录。
- 2027年初同位素收入目标若兑现，将使Oklo从纯开发叙事向早期商业收入过渡。
主要风险
- 本次内容没有披露新增合同金额、客户、产能利用率或监管节点，短线更可能被市场视为旧里程碑再传播。
- Oklo商业核电和同位素业务仍面临许可、燃料、工程放大和收入兑现不确定性。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-08-06 · 影响 weakens
反向证据不是基本面利空，而是核心临界事实已提前近一个月公开披露，削弱本次追多的新鲜度。
检索:Oklo Groves criticality August 2026 first commercial isotope revenue early 2027 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足没有改变最终结论；核心否决点是新增事实不足。
方向:未取得足够同市场、同机制且首发锚点干净的先例来支持短线交易。
涨幅量级:本次结论不依赖先例幅度校准，因为事件被判定为旧事实再传播而非新增里程碑。
形态:无足够样本判断是否存在反复见光死，但旧里程碑再传播本身提高price-in风险。
工具执行结果 · 成功 2 · 降级 0 · 失败 0 · 取消 0
- web_search 成功 ? · 0 ms
- web_search 成功 ? · 0 ms
原文全文
展开原文 · 917 字
Reaching criticality at Groves was a major milestone. It was also just the beginning.
In less than a year, Oklo built our Groves Isotope Test Reactor from the ground up and brought it to criticality, demonstrating our ability to move from design to operation on a timeline few thought possible.
What we learned extends far beyond Groves. The project gave our team hands-on experience across engineering, construction, regulatory execution, startup, and operations that we can apply as we advance projects across power, fuel, and isotopes.
Now, we're putting that experience to work as we build toward commercial scale. That includes targeting our first commercial isotope revenue in early 2027 through our NRC-licensed Idaho Radioisotope Laboratory, while advancing our power and fuel projects toward deployment.
Groves demonstrated our ability to build, learn, and repeat. Now, we're doing it across the business.
In less than a year, Oklo built our Groves Isotope Test Reactor from the ground up and brought it to criticality, demonstrating our ability to move from design to operation on a timeline few thought possible.
What we learned extends far beyond Groves. The project gave our team hands-on experience across engineering, construction, regulatory execution, startup, and operations that we can apply as we advance projects across power, fuel, and isotopes.
Now, we're putting that experience to work as we build toward commercial scale. That includes targeting our first commercial isotope revenue in early 2027 through our NRC-licensed Idaho Radioisotope Laboratory, while advancing our power and fuel projects toward deployment.
Groves demonstrated our ability to build, learn, and repeat. Now, we're doing it across the business.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。